Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod
The US FDA gave the drug a broad label in adults with indolent SM, without restrictions for disease severity or prior treatment, and Blueprint sees a potential $1.5bn market opportunity.
You may also be interested in...
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Detailed data in indolent systemic mastocytosis show improvement across primary and key secondary endpoints, but analysts pointed to lower improvement on symptoms outside of those affecting the skin.
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.